MedTrace Logo

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

NCT07309055 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 201

Last updated 2026-04-07

No results posted yet for this study

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis.

Conditions

  • Adolescents With Moderate-to-severe Atopic Dermatitis

Interventions

DRUG

SHR-1819 Injection

SHR-1819 injection.

DRUG

SHR-1819 Injection Placebo

SHR-1819 injection placebo.

Sponsors & Collaborators

  • Guangdong Hengrui Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-21
Primary Completion
2027-11-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07309055 on ClinicalTrials.gov